VERICI DX PLC Logo

VERICI DX PLC

VRCI | IL

Overview

Corporate Details

ISIN(s):
GB00BM8HZD43
LEI:
213800FI5WE4FVQ3G645
Country:
United Kingdom
Address:
AVON HOUSE, CF64 2EZ CARDIFF
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Verici Dx PLC is an immuno-diagnostics development company specializing in the kidney transplant market. The company develops and commercializes a suite of advanced prognostic and diagnostic tests that form a comprehensive kidney transplant platform. Leveraging artificial intelligence-assisted transcriptomic analysis, its technology deciphers RNA signatures to provide data-driven insights into the body's immune response. These tests offer personalized patient and organ response risk assessments to assist clinicians in medical management throughout the transplant process, from pre-transplant evaluation to late-stage monitoring. The core mission is to predict the risk of organ injury, rejection, and graft failure, ultimately improving patient outcomes and overall graft survival. The company also collaborates with biopharmaceutical and data science partners to foster innovation.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for VERICI DX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-01 11:40
Major Shareholding Notification
Holding(s) in Company
English 51.2 KB
2025-07-31 18:28
Major Shareholding Notification
Holding(s) in Company
English 40.6 KB
2025-07-31 16:24
Major Shareholding Notification
Holding(s) in Company
English 52.9 KB
2025-07-31 08:00
Regulatory News Service
Tutivia™ abstracts for World Transplant Congress
English 15.3 KB
2025-07-30 15:32
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-07-30 15:26
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2025-07-30 08:00
Post-Annual General Meeting Information
Result of Annual General Meeting
English 17.8 KB
2025-07-29 08:00
Share Issue/Capital Change
Result of WRAP Retail Offer
English 27.3 KB
2025-07-28 18:19
Major Shareholding Notification
Holding(s) in Company
English 53.2 KB
2025-07-28 17:55
Major Shareholding Notification
Holding(s) in Company
English 51.6 KB
2025-07-28 11:23
Major Shareholding Notification
Holding(s) in Company
English 22.9 KB
2025-07-25 18:22
Major Shareholding Notification
Holding(s) in Company
English 25.8 KB
2025-07-25 14:05
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-07-25 14:04
Major Shareholding Notification
Holding(s) in Company
English 40.6 KB
2025-07-22 08:00
Share Issue/Capital Change
WRAP Retail Offer for up to £500,000
English 33.2 KB

Automate Your Workflow. Get a real-time feed of all VERICI DX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for VERICI DX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland FARN
Fluicell AB Logo
Developing bioprinted tissues for regenerative medicine and advanced drug screening.
Sweden FLUI
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark FLUO
FUSION ANTIBODIES PLC Logo
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
United Kingdom FAB
FUTURA MEDICAL PLC Logo
Develops topical sexual health gels, including a fast-acting, over-the-counter ED treatment.
United Kingdom FUM
Gabather AB Logo
Clinical-stage pharma developing GABAA therapeutics for neuropsychiatric disorders.
Sweden GABA
GEIGER COUNTER LIMITED Logo Jersey GCL
Geneuro Logo
Develops HERV-targeting treatments for neurodegenerative and autoimmune diseases.
Switzerland GEM
GENFIT Logo
Biopharma firm developing therapies & diagnostics for rare and severe liver diseases.
France GNFT
GENFLOW BIOSCIENCES PLC Logo
Developing gene therapies to target the aging process in humans and dogs.
United Kingdom GENF